Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly ...

It has been about a month since the last earnings report for Regeneron (REGN). Shares have lost about 4.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Sanofi Consumer Healthcare Indias shares finished Thursday 1.42% higher at Rs 4,815 a share, with a market capitalisation of ...

Novavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...

Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...

Berenberg analyst Luisa Hector raised the firm’s price target on Sanofi (SNY) to EUR 120 from EUR 115 and keeps a Buy rating on the ...

Paris, March 5, 2025. Sanofi announces that it has successfully priced its offering of EUR 1.5 billion of notes across 2 tranches: €850 million floating rate notes, due March 2027, bearing interest at ...

Zandy Forbes’ biotech company MeiraGTx has developed targeted gene therapy methods to treat more than just genetic disorders.

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

South Africa's Competition Commission investigates Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market.

South Africa's competition watchdog launches a crucial investigation into pharmaceutical giants Novo Nordisk and Sanofi over ...

Sanofi SA has described Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of allergy, pain, dermatological and inflammatory disorders.